Specifically, this pilot study examined if systemic markers of intestinal barrier integrity (LPS binding protein (LBP), intestinal fatty acid binding protein (IFABP)) or serum BDNF levels collected from older adults without clinical evidence of AD dementia were associated with risk of death, incident AD dementia or MCI, or cognitive impairment. This evidence concerns the gene FABP2 and Cognitive impairment.